News Listing

We are pleased to announce that Tebubio has received funding from the French Government to further improve the performance and development of its RNA activities: https://www.tebubio.com/blog/highlight/accelerate-your-mrna-research-st… 
Thanks to this funding, Tebubio will continue to develop its Contract Research Services to support researchers based in UK and abroad, in order to facilitate ...

The seventh Birmingham-born company has entered University of Birmingham Enterprise’s award-winning Med Tech incubator, Unit 9.

Produced using dry-spun 50 µm Collagen Type I fibers, AMSBIO has introduced the innovative CollaFibR™ additive proven to increase the shape fidelity and biological relevance of bioprinted constructs in hydrogels and bioinks.

In the field of personalized tissue engineering, 3D bioprinting shows immense promise, but the challenge lies in achieving both mechanical durability and biological ...

UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets.

Bio-Rad's Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.

AMSBIO has launched an enhanced GMP-compliant version of its animal-origin-free, chemically defined StemFit™ iPSC expansion medium.

CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first close of its Series B fundraising round. The funding has been secured from several new investors; including $10 million from Bayland Capital, and $5.5 million from founding shareholder, CN Innovations Holdings Ltd. The investment will be used to ...

Rinri Therapeutics, a leader in regenerative cell therapies for sensorineural hearing loss, is pleased to announce the appointment of David Hipkiss as its new Independent Chair. This strategic move comes at a pivotal time as the company prepares to initiate first-in-human trials for its lead asset, Rincell-1.

OBN’s annual BioTrinity conference, held this week in London, was bigger and better than ever. Attended by record numbers of life sciences delegates, the event proved to be an invaluable opportunity for sector professionals to network and forge new contacts, with a remarkable 9,000 partnering meetings requested, and more than 1,500 of these taking place on site, all designed to fuel deal-making ...

OBN’s BioTrinity 2024 has been the biggest yet! And a recurring message throughout the second day of the conference was one of ‘going big’. Big on approach, big on optimism and big on ambition.